Revvity (RVTY)

• Market cap: $13.9B
• 1 day: -0.77%
• 5 days: 0.13%
• 1 month: -8.16%
• 3 months: 2.46%
• 6 months: -5.71%
• Year to date: 1.64%
• 1 year: 9.70%
• 5 years: 22.61%
• 10 years: 143.46%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Employees: 11,500

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

23% more repeat investments, than reductions

Existing positions increased: 189 | Existing positions reduced: 154

20% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $1.48M

3.3% more ownership

Funds ownership: 88.0% [Q3] → 91.3% (+3.3%) [Q4]

8% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 59

5% less capital invested

Capital invested by funds: $13.8B [Q3] → $13.2B (-$633M) [Q4]

2% less funds holding

Funds holding: 516 [Q3] → 505 (-11) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $138 21% upside
• Avg. target: $142 25% upside
• High target: $145 27% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	23% upside $140	Overweight Maintained	3 Feb 2025
Raymond James Andrew Cooper 14% 1-year accuracy 2 / 14 met price target	27% upside $145	Outperform Reiterated	3 Feb 2025
Keybanc Paul Knight 33% 1-year accuracy 3 / 9 met price target	27% upside $145	Overweight Maintained	3 Feb 2025
B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	21% upside $138	Buy Upgraded	13 Dec 2024